Aura Biosciences, Inc. (AURA) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value |
| Current obligations | 19.56M USD | Liabilities, Current |
| Cash and equivalents | 67.84M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory · excluded from quick assets | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $19.56M | $67.84M | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | $16.71M | $84.79M | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | $18.38M | $59.52M | (m) | (m) | (m) | (m) |
| 2025-09-30 | (m) | $18.82M | $47.55M | (m) | (m) | (m) | (m) |
| 2025-06-30 | (m) | $14.85M | $107.37M | (m) | (m) | (m) | (m) |
| 2025-03-31 | (m) | $12.16M | $38.23M | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | $14.91M | $31.69M | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | $14.71M | $25.41M | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $10.55M | $30.07M | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | $9.66M | $26.28M | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | $12.36M | $41.06M | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | $10.89M | $55.58M | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | $8.89M | $47.73M | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | $8.11M | $38.49M | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | $10.46M | $121.58M | (m) | (m) | (m) | (m) |
| 2022-09-30 | (m) | $9.96M | $61.11M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $5.81M | $53.85M | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $5.00M | $108.38M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $7.27M | $149.06M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $5.83M | $81.83M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | $92.20M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | $99.67M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.66M | $17.39M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | (m) | $11.30M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |